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Abstract: The top priority of any nation is to lead the nation towards prosperity, progress, and economic growth, confronting several
challenges and concerns arisen from global situations. The sudden outbreak of any disease defies the health care systems and economy
of nations. COVID-19 is one of the viral diseases which broke out in Wuhan city of China in 2019. COVID-19 outbreak intermittently
prevailed all over the world. It exposes the fragility of the established health care systems across the world in spite of comprising
modern science and technology. Unfortunately, there is no chemotherapeutic agent in the regimen of antiviral drugs or no vaccine
available to curb this infectious disease. As a consequence, this deadly infection has prevailed all over the world. The antiviral drugs
used for viral diseases excluding COVID-19 infection are Ramdesvir, Favipiravir, and Ribavarin, and antimalarial agents (Chloroquine
& Hydroxychloroquine) are being administered to the patients for redemption of this infection. Fortunately, these existing drugs have
been found clinically active and are being used. In this review, we present the current scenario and status of epidemiology, diagnosis,
treatment, vaccine development for COVID-19, and its impact on the socio-economic structure.
Key words: COVID-19, transmission rate (Ro), mortality rate, vaccines, antivirals, financial crisis

1. Introduction
Coronavirus is one of the lethal viruses that human race
have ever seen. Indeed, coronavirus is a single-strand
RNA virus that utilizes host cells for the replication of
their genome (Bhupender et al, 2020; Ju et al., 2020) the
immediate emergency therapy is not available for the
treatment of this disease, leading to widespread fear of
infection and has created social issues for infected peoples.
The SARS-CoV-2 genomes encode a protein which is
known as RNA-dependent RNA polymerase (RdRp).
Through this, new copies of RNA virus are transcribed in
the host cells by viral genome. Thus, replication of RNA
inhibition is quite important to control infections. These
viruses have been categorized into four types as alphacoronavirus, beta-coronavirus, delta-coronavirus, and
gamma-coronavirus. Among these, α and β CoVs are
known to be the causative agents of infections in humans
(de Wilde et al., 2017a). HCov 229E, NL63, OC43, and
HKU1 are the four globally endemic human coronaviruses
(HCoVs) which are accountable for 10% to 30% of upper
respiratory tract infection in adults. A large variety of
ecologically diverse coronaviruses are mainly seen in bats,

which are also the reservoir for many of these viruses (de
Wit et al., 2016). Coronaviruses have been named for the
crown-like spikes on their surface which are glycoprotein,
critical for binding of host cell receptors and are believed
to represent a key determinant of host range restriction.
The HCoVs earlier received quite low attention due to
their mild effect in humans. However, in 2002, it emerged
as an important human pathogen when the cases of severe
atypical pneumonia emerged in China, causing a largescale epidemic. More than 774 deaths in total, and more
than 8000 infections caused worldwide concern. This new
disease was further named as severe acute respiratory
syndrome CoV (SARS-CoV), and a beta-HCoV, named
SARS-CoV, was identified as the causative agent. Over
a decade in 2012, Middle East respiratory syndrome
(MERS-CoV) caused panic and a persistent epidemic in
the middle eastern countries (Cheng et al., 2007; Chan
et al., 2015). In both cases, there was history of human–
animal contacts, so zoonotic transmission of HCoVs was
highly suspected, and a consensus emerged that bats were
the natural hosts and the virus transmitted into another
amplification mammalian host [masked palm civet
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(Pagumalarvata) for SARS-CoV and dromedary (Camelus
dromedarius) for (MERS-CoV)] before crossing species
barrier to infect humans.
Coronavirus disease 2019 is a contagious disease
caused by SARS family virus SARS-CoV-2. The initial
symptoms of COVID-19 are coughing, throat infection,
fever, breath shortness, muscle pain, and fatigue, and later
the symptoms become severe pneumonia, kidney failure,
and acute respiratory distress syndrome (ARDS). The
incubation period for exposure to onset is 2 to 14 days
according to WHO and the US Center for Disease Control
and Prevention. A full genomic sequence of COVID-19,
known as SARS-CoV-2, was released by the Shanghai
Public Health Clinic Center (SPHCC) and School of Public
Health (SPH) and their collaborators to public data in this
havoc outbreak response. We can access the complete
genome sequence of SARS-CoV-2 (Wuhan-Hu-1) from
GenBank (Accession no: NC_045512/MN908947.3).
2. Demography: global health emergency and current
status
On December 1, 2019; numerous pneumonia cases were
reported to the World Health Organization (WHO) by the
Chinese Health Authority in Wuhan city, Hubei Province,
China (WHO, 2020a). The earliest signs of these patients
include fever, malaise, dry cough, and dyspnea. The CT
scan of these patients shows pneumonia with abnormal
findings and COVID-19 was detected in virological tests
of these patients. In just 4 months, the COVID-19 that
originally emerged in the Wuhan city of China poses a
major public health issue and governance challenges. The
disease has now spread throughout the world. There was
an unknowingly large spread of the infection through
human-to-human transmission among the national and
international travelers during the Chinese New Year
holidays, which resulted in the mobility of the virus
globally.
COVID-19 is affecting more than 210 countries and
territories, and some countries are more affected, such as
the USA, Spain, Italy, France, Germany, UK, Turkey, Iran,
and China. The estimated mortality rate is 3.4% by WHO
as of March 3. The basic reproduction number (R0) for
COVID-19 so far seems to between 2.5 and 2.79 although
the current R0 value might be biased because of insufficient
data. The current R0 value of COVID-19 is much lower in
comparison to other viruses like chickenpox, mums, and
SARS (Figure 1) but many experts have suggested that
COVID-19 may be far more infectious than the flu. If we
go through the stats, we will notice a significant change
in the mortality rate of most of the countries over time.
Also, the accurate data of the mortality rate of different
countries are still unavailable and now the logarithmic
curve of per day new cases and deaths from the previous
active cases could be considered one of the reasons for
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the escalation in the mortality rate of those countries.
However, if we look at the macroimage of the complete
stats, it will show a consistent trend of increase in the
number of per day new cases marked by many countries
like the USA, Spain, Italy, UK, Russia, France, Germany,
Turkey, Brazil, and Iran. However, it is too early now to
consider these data to compare the current mortality rates
and demographics of countries, since each of these or
other countries are in the different stages of the COVID-19
pandemic. For instance, it is unscrupulous to compare the
current mortality rate of Spain, USA, Italy, and France with
that of India, Pakistan, and Bangladesh, as the countries
in these categories are currently having different stages of
the outbreak. In addition, many other factors affect the
stats of mortality rate are age, smoking, and comorbidities
in many countries [6]. As of May 8, 2020; more than 3.9
million infected cases with 270 thousand deaths around
the globe have been reported. At present, no vaccine or
specific treatment is available, which makes it more deadly.
3. The coronavirus disease (COVID-2019): SARS-CoV-2
virus
The outbreak of the respiratory syndrome causing a
major epidemic by the coronavirus family was named
temporarily as 2019 novel coronavirus (COVID-19)1. Here
the word novel refers to emerging human disease by this
coronavirus family which required further studies (Chen
et al., 2020). Further, it was revealed in the genetic analysis
of the COVID-19 that the virus was noticeably similar
(with up to 88%) to the bat-derived (SARS). Regardless
the variation of the amino acid at a few key residues,
homology modeling showed that COVID-19 has a similar
receptor binding domain structure to that of SARS-CoV
(Lu et al., 2020). Similarly, the catalytic sites of the four
COVID-19 enzymes that could represent antiviral targets
are remarkably conserved and have mutual sequence
similarity with the corresponding enzymes of SARS and
MERS (Li and De Clercq, 2020; Liu et al., 2020). The
International Committee on Taxonomy of Viruses (ICTV),
which is responsible for officially classifying and naming
of the family Coronaviridae, is the Coronavirus Study
Group (CSG). This novel virus was formally recognized
by CSG as a sister to the (SARS-CoVs) and assigned it
as (SARS-CoV-2) (Gorbalenya et al., 2020). Further, the
WHO and ICTV confirmed and announced the name of
the virus as (SARS-CoV-2), and its disease outbreak as
COVID-19, which refer to the disease or illness caused by
this SARS-CoV-2. It is a functional naming convention
with a standard format and can be used for any future
outbreak of coronavirus2.
1
Coronavirus disease (COVID-19) outbreak. [online] Website:
https://www.who.int/westernpacific/emergencies/covid-19 [accessed 7 May 2020]

Cohen J. COVID-19: Why names of new infectious diseases
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4. Clinical manifestation and complication
The most common symptoms of COVID-19 at the onset
of illness were fatal pneumonia, fever, headache, cough,
sputum production dyspnea, myalgia, fatigue. Older
patients (aged >60 years) with comorbidities appear
to be more vulnerable to becoming severely ill with
the infection and had more systemic symptoms. The
incubation period for the infection with SARS-CoV-2
ranges from 2 to 14 days after exposure. The zoonotic
coronaviruses were identified as severe human pathogens
in the previous outbreak of (SARS) at the beginning of
2003 and Middle East respiratory syndrome in 2012 (Chan
et al., 2015). However, the clinical presentation, symptoms,
and complication in both these outbreaks share many
resemblances with the recent Coronavirus (COVID-19).
The infection has been associated with complications like
organ dysfunction (acute respiratory distress syndrome
[ARDS], acute cardiac injury, acute kidney injury, septic
shock) and severe cases result in the death of the patient
matter. [online] Website: https://www.forbes.com/sites/joshuacohen/2020/02/13/covid-19-why-names-of-new-infectious-diseases-matter/#1f1a7b16ac63 [accessed 7 May 2020]

(Wang et al., 2020). Besides, many countries, including
China and India, have reported the asymptomatic cases of
COVID-19. The asymptomatic patients cause concerns of
a next wave of infections amid the relaxation of stringent
measures in the country initiated to contain the lethal
disease.
5. SARS-CoV-2 transmission in humans
The majority of the initial infected cases were linked to
Huanan seafood and wild animal wholesale market, which
has been marked as the epidemic center by the Chinese
health authority. It is believed that the virus possibly
originated from horseshoe bats in China and then was
transmitted to other animals which are usually eaten
by humans. Also, based on their research, South China
Agricultural University claimed that the pangolin too acts
as the key source of novel coronavirus (COVID-19) after
the genetic comparison of COVID-2019 taken from the
infected humans and animals in their research and they
noted the similarity of 99% in their genetic sequences
(Cyranoski, 2020). The following common modes of
infection transmission have been reported:

Figure 1. Average basic reproduction number (R0) of most common viruses.
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5.1. Through animals
The majority of COVID-19 infection cases shared the
history of zoonotic transmissions like SARS-CoV and
MERS-CoV because many of the first individuals found
to be infected by the virus were workers at the Huanan
seafood market. According to the US-based Center for
Disease Control and Prevention (CDC), the Wuhan
coronavirus likely started from a “spillover” that occurs
when the virus was passed from animal to human. These
spillovers are reported to ensue through close humanto-animal contact, particularly in wet markets (Li et al.,
2019). In the same way, to justify the transmission through
animals, a “snake theory” was very popular. A study claims
there is evidence that COVID-19 came from snakes sold
at the Wuhan market. They found that the virus appears
to be a mix or “recombination” of two coronaviruses,
Homologous recombination within the spike glycoprotein
of the recently recognized coronavirus may increase cross‐
species transmission from snake to human (Ji et al., 2020).
It has shown that approximately CoVs have been spotted
in bats in China. A large amount of evidence suggests that
there is a link between COVID-19 and other known CoVs
in bats, specifically in Rhinolophus bat subspecies which is
abundant and mostly present in Southern China, and across
Asia, the Middle East, Africa, and Europe regions (WHO,
2020b; Wang et al., 2018). However, few investigators have
advocated that the Huanan seafood market may not be
the original source of the viral transmission to humans
(Cohen, 2020).
5.2. Human-to-human transmission
Potential asymptomatic transmission and human-tohuman transmission has been reported for most of
the infection within the family members, office crew,
healthcare practitioners, through air travels, and from
a person who had recently travelled or repatriated from
infection-prone countries (Chan et al., 2020). It is a vertical
transmission when an infectious agent is transmitted from
mother to baby during the period immediately before and
after birth. The first known case of vertical transmission
in China was reported on 5 Feb 2020. However, it is still
unclear whether the newborn was infected with SARSCoV-2 through vertical transmission or contracted the
virus from the hospital environment. Still, much research
and information are needed in this case.
5.3. Fecal transmission
Recently, Chinese researchers found that COVID_19 was
present in the feces of infected people, which may help to
elucidate why it spread so fast on cruise ships (Diamond
Princess). Also with a negative result in respiratory tract
sample and presence of SARS CoV-2 RNA in patients’
fecal sample at an average of 11 days might be confirmed
through the stool which can further contaminate the
hands, food, and water bodies3.
Gale J. Fecal transmission may be behind coronavirus’s rapid
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6. Transmission stages
In stage 1, the cases are imported from infection-prone
countries and the virus does not spread locally. At this
stage, it is easy to test, track, and treat the patients. When
it comes to stage 2, the virus could be transmitted through
contact with affected people. Here, the most affected
people are their family members, friends, and people
who come in contact with them. The third stage is the
community transmission where an individual becomes
infected without any travel history to affected countries,
and nobody knows the exact source of the virus. This stage
is extremely infectious and difficult to control in densely
populated countries like India, Bangladesh, and China.
Stage 4 is the worst form of disease transmission which is
totally out of control, such as it was in the US, Spain, Italy,
France, and Germany.
7. Vaccines and antivirals: current status and future
directions
At present, no vaccine or specific treatment is available;
however, Chinese health authorities endorsed the use
of traditional Chinese medicine (TCM) for infected
individuals with COVID-19. Additionally, many drug
companies are claiming to have developed like the Indiabased pharmaceutical firm Zydus Cadila4, which has
recently started DNA vaccine development program
against the COVID-19 (Pharmaceutical Tech., 2020).
Moreover, the Health and Human Services (HHS), USA,
Sanofi Pasteur and Johnson & Johnson have taken the
initiative to develop vaccine and therapeutics to use
against COVID-195,6. In a similar way, the Taiwan-based
company “Medigen Vaccine Biologics Corp (MVC)”
recently publicized that it has teamed up with the US
National Institutes of Health (NIH) to develop a vaccine
against COVID-197. On 21 Feb 2020, a researcher from
spread. [online] Website: https://www.bloomberg.com/news/
articles/2020-02-20/fecal-transmission-may-be-behind-coronavirus-s-rapid-spread [accessed 7 May 2020].
4
Zydus Cadila looks to expedite Covid-19 vaccine development.
[online] Website: https://www.pharmaceutical-technology.com/
news/zydus-cadila-covid-19-vaccine/ [accessed 7 May 2020]
5
Soucheray S. HHS partners with drug makers on COVID-19
vaccine, drugs. [online] Website: https://www.cidrap.umn.edu/
news-perspective/2020/02/hhs-partners-drug-makers-covid19-vaccine-drugs [accessed 7 May 2020]
6
SARS treatments could help with the new coronavirus. Why were
they shelved? [online] Website: https://fortune.com/2020/02/18/
coronavirus-sars-vaccine-development/ [accessed 7 May 2020]
7
Taiwan firm teams up with US to develop Covid-19 vaccine,
2020. [online] Website: https://www.thestar.com.my/news/regional/2020/02/17/taiwan-firm-teams-up-with-us-to-developcovid-19-vaccine [accessed 7 May 2020]
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Tulane University (US) also announced to have developed
a vaccine, and named it COVID-198.
In the era of advanced and effective vaccines and
antiviral therapeutics, COVID-19 again proved that we
are nothing in front of the nature and it presents a major
threat to human beings. However, many research projects
are being run to develop better treatments.
7.1. DNA vaccination
The genetically modified DNA is injected into the cells
so it can directly manufacture an antigen which gives a
defensive immunological response.
7.2. Live-attenuated investigational vaccine (LAIV)
The LAIV can protect from COVID-19. In this type of
vaccine, the virus has been incapacitated so that it cannot
cause disease.
7.3. Investigational mRNA vaccine
The mRNA has been introduced as a very flexible
and efficacious stage to deliver vaccine antigens and
therapeutic proteins and can be easily altered to express
most viral proteins and can be produced efficiently (Alam
et al., 2017).
7.4. Plasma protein therapies
Patients who recovered from COVID-19 still have
antibodies in their bodies. By injecting these antibodies
into a new COVID-19 patient (immunity transfer) can
help to overcome it9,10.
7.5. The spike glycoprotein
It is the major surface protein that the virus uses to bind to
a receptor and it acts as a doorway into the human cell. The
viral membrane fuses with human cell membrane allowing
the genome of the virus to enter into the human cell and
begin infection; if we can prevent attachment and fusion,
we can prevent the entry of the viruses (Cohen, 2016).
Thus, these spike proteins can be new targets in the fight
against COVID-19.
7.6. COVID-19 Neutralization
We can control COVID-19 by recognizing its transmission
mechanism in humans. The elucidation of the molecular
crosstalk that links COVID-19 interaction with the host
cell receptors that cause infections, replication of virus and
involved signaling pathways in the immune response will
give the basic understanding about its pathogenesis.
8
Tulane University to develop vaccine for novel coronavirus.
[online] Website: https://www.pharmaceutical-technology.com/
news/tulane-univeristy-coronavirus-vaccine/ [accessed 7 May
2020]

Saplakoglu Y. Blood from cured coronavirus patients could help
treat infection. [online] Website: https://www.livescience.com/
blood-plasma-cured-patients.html [accessed 7 May 2020]
9

Novel Coronavirus(2019-nCoV) (Situation Report – 22 ). [online] Website: https://apps.who.int/iris/handle/10665/330991
[accessed 7 May 2020]
10

7.7. Chemotherapeutic agents
Although there are no chemotherapeutic agents available
to curb this menace, few agents are being exploited.
Some of them are antiprotozoal regimen and others are
antivirals. Chloroquine, Hydroxychloroquine, Sofosbuvir,
Remdesivir, Favipiravir, Disulfiram, Ritonavir, Lopinavir
are chemotherapeutic agents (Figure 2) that are being
exploited to circumvent novel-Covid-19. Until the
discovery of drugs for the virus, these existing drugs are
Hobson’s choice for the treatment of the corona virus. It
is well known that corona viruses are RNA viruses which
utilize the host cells for the replication of their genome.
The corona virus genomes encode a protein which is
known as RNA-dependent RNA polymerase (RdRp).
Through this, new RNA copies are transcribed into the
host cells by viral genome. Thus, replication of RNA
inhibition is quite important to control infections. In
this pursuit, RNA-dependent RNA polymerase (RdRp)
is one of the most significant targets to discover new
chemotherapeutic agents. Nucleosides and nucleotides of
RNA-bases are being exploited as pro-drug to inhibit RNA
polymerase. Sofosbuvir and Remdesivir as displayed in
Figure 2, are such examples of pro-drugs. These are RNA
polymerase inhibitors and are under clinical trials to treat
COVID-19 (Holshue et al., 2020a; Wang et al., 2020a). The
corona virus enzyme is able to accept modified nucleotide
analogues due to its error-prone nature. Thus, nucleosides
and nucleotides which inhibit polymerase are an important
class of antiviral agents (Oberg, 2006; Eltahla et al., 2015).
For future perspective, RNA-polymerases inhibitors are
promising.
7.8. Failover
It shows anti-COVID-19 activity by blocking the enzyme
the virus needs to survive in the host11.
7.9. Chloroquine and Remdesivir
These two drugs are antimalaria drugs and currently under
assessment in more than 100 patients at over ten hospitals
in Beijing and Guangdong provinces. Chloroquine
prevents viral infections by increasing the endosome pH
required for virus/cell fusion and interfering with the
glycosylation COVID-19 cell receptors. A study by NIH
officials confirms that the positive effect of Remdesivir
drug against the MERS-CoV and COVID-1912,13, (Holshue
et al., 2020b).
https://www.pharmaceutical-technology.com/news/china-approves-favilavir-covid-19/
11

12
Antimalarial drug confirmed effective on COVID-19. [online]
Website:
http://www.xinhuanet.com/english/202002/17/c_138792545.htm [accessed 7 May 2020]
13
Preclinical data of Gilead’s remdesivir raises hope for China trials. [online] Website: https://www.pharmaceutical-technology.
com/news/nih-gilead-remdesivir-monkey-data/ [accessed 7 May
2020]
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Figure 2. The chemotherapeutic agents exploited to curb the disease produced by COVID-19.

7.10. HIV medication
Two existing drugs, Ritonavir and Lopinavir, are used in
combination for HIV but due to lack of a specific drug
for COVID-19, Chinese health authorities recommended
these drugs14.
7.11. Favipiravir
It is an approved drug for influenza, which inhibits the
RNA-dependent RNA polymerase of RNA viruses, and a
recent study reported its activity against COVID-19 (De
Clercq, 2019; Wang et al., 2020b).
7.12. Ribavirin
It is an approved drug for treating hepatitis C virus
(HCV) and respiratory syncytial virus (RSV). Previously,
Ribavirin was used in SARS and MERS patients (Zumla
et al., 2016) and it may offer sufficient potency against
COVID-19.
7.13. Disulfiram
It is an approved drug for alcohol addiction. It has been
reported to inhibit the papain-like protease of MERS and
SARS in in vitro but in vivo evidence is not available. At
this critical situation, Disulfiram drug can be tested against
COVID-19.
Results from Covid-19-focused trials in China may come within weeks. [online] Website: https://www.clinicaltrialsarena.com/
news/china-covid-19-trials/ [accessed 7 May 2020]
14
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7.14. Hydroxychloroquine
It is used to cure patients with a disease like lupus, malaria,
and rheumatoid arthritis for decades. Earlier in several
studies, due to its antiviral activity and its potential to
amend the immune system activity of Hydroxychloroquine
alone or in combination with Azithromycin, it was
believed that it might also be efficacious in COVID-19
treatment. However, the latest study evaluating data from
368 COVID-19 patients treated with Hydroxychloroquine
alone or in combination with Azithromycin antibiotics
show no benefits; instead, higher death rates were reported
in the patients who were taking these medications. As per
the data, 97 patients who took Hydroxychloroquine had
a 27.8% death rate and the remaining 158 patients who
did not take the drug had 11.4% of death rate (Magagnoli
et al., 2020). Hence, these drugs still need to be studied
before their widespread adoption.
Besides the drugs above, a list of anticoronavirus agents
(in preclinical stage) is given in Table.
8. Prevention and treatment
It is well said that “prevention is better than cure.” We do
know that COVID-19 is an infectious disease outbreak.
Since it is a new virus, there is currently no vaccine or
specific treatment, and the understanding of the virus and
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the disease are still evolving. Currently, in the absence
of any proven therapy for COVID-19, the mainspring
care for the infected patients is still supportive care from
symptomatic outpatient management to full intensive
care support. The most efficacious abiding strategy for
prevention of COVID-19 outbreak in the future would
be the development of a vaccine to avert the infection
and to provide protective immunity among people. Many
research groups have designed potential vaccines and
are in clinical phase; however, there is much more work
to do. Thus, for now, we need to apply basic cautions
like hand hygiene, coughing etiquette, putting a mask
on face, avoiding close contact with people showing
symptoms of respiratory diseases, and inform a doctor
when feeling sick. Many countries imposed stay-athome orders or lockdowns as a preventive measure of
the further transmission of the infection, as quarantine
and social distancing is a very notable factor to cease the
transmission. Hence, it is recommended to avoid large
crowded public places and to maintain at least 6 feet of
distance between yourself and others, especially if you
are around ill people. People with older age and those
with comorbidities need extra care, and they should also
avoid unnecessary travel. Frequent hand washing for at
least 20 s is the best way to protect yourself and your
loved ones.
9. The of COVID-19 on the global economy
COVID-19 had a major impact on the global economy
throughout the first quarter of 2020. More than 210
countries are affected by this pandemic leading to almost
half of the world population on lockdown to prevent the
spread of deadly COVID-19 virus. The Economist forecasts
the slowing of the global economy by 6% in 2020, 0.7%
of growth, and an average of 1.2% contraction. Countries
which are experiencing the economic shock of COVID-19
pandemic include US (–5.9%), Japan (–5.2%), UK
(–6.5%), Germany (–7.0%), France (–7.2%), Italy (–9.1%),
Spain (–8.0%). Also, the Central Asian Countries and
Middle East countries will be shrunk by 2.8% with Saudi
Arabia’s growth forecast at –2.3%. As the world’s largest
manufacturing economy, China evolves its manufacturing
capabilities to supply products from low-cost goods to
more advanced ones globally has now been decelerated
due to this vicious viral outbreak. As the factories in most
of the countries are still shut due to the outbreak and also
due to unavailability of transport, travel, and labor supply
because of restriction on movement and social distancing
which eventually results in disrupted supply and lost
revenue in business. And now, there has been the complete
shutdown of all sectors, including nonessential retail
trade, hotels, restaurants, and tourism. The disruption of
the supply chain and unavailability of medical supplies

and drugs around the world could be seen because of
the Chinese dominance in the pharmaceutical market as
it is the dominant and often the only global supplier for
the active ingredients of some vital medication, medical
devices, and equipment.
The tourism industry is currently one of the most
affected sectors by COVID-19, which holds 10% of global
GDP. The pandemic could affect more than 50 million jobs
globally in this industry. As a result of flight cancellations,
the global airline revenues are expected to dive by 4–5
billion $ in the first quarter of 2020. As per the forecast
by the UN’s International Civil Aviation Organization
(ICAO) and World Travel and Tourism Council (WTTC),
International travel could be adversely struck by up to
25% in the year 2020. Also, due to lockdown and travel
restrictions, the demand for oil has reduced worldwide.
The unprecedented drop in oil price below zero $ for
the first time in history has been experienced due to
the sapped demand for oil because of the COVID-19
pandemic. The catastrophic imbalance of oversupplied oil
in the market causes the West Texas Intermediate (WTI), a
global benchmark for oil prices, costs less than zero dollars
on April 19, 2020.
10. Discussion
Coronavirus disease, which started in the last month of
2019, has spread its feet almost all over the world. It hit
every sector of the world, from a survival level to large
scale business, created fear of death and uncertainty. It has
forced the world to stay at home. Since the beginning of
its outbreak with the infection until 06 May 2020, more
than infected cases with deaths around the globe have
been reported. The initial infected cases of COVID-19
were directly or indirectly linked to Huanan seafood
and wild animal wholesale market, where it was possibly
transmitted through bats. After all, now it has expanded
its modes of transmission like, through animals, human
to human, and fecal transmission. After inhaling into the
body it takes around 2 to 14 days to incubate, and the
journey begins with normal symptoms like cough, fever,
etc. to severe illness and in the end death due to weakness
of immunity. Some other factors are also responsible for
increasing death rate like lifestyle, age (main factor), and
weak immune system due to having another disease.
Among more than 210 countries the report says developed
countries are most affected by this pandemic. It has
been seen that COVID-19 may be far more infectious
in comparison to other flu infections, because R0 value
is lower than other viruses, like chickenpox, mums, and
SARS.
The whole world is currently engaged in research on
COVID-19 to control it. A genetic study has revealed
its sequence similarity with previous with SARS and
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Table. List of antiviral compounds against human coronaviruses.
S.No Antiviral agents

Drug targets/Mechanism

References

Inhibits RdRp

(Wang et al., 2020c)

Virus-based treatment strategies
1

Penciclovir

2

Galidesivir

Inhibits viral RNA polymerase function

(Warren et al., 2014)

3

Thiopurine analogues

Inhibits PLpro

4

Lopinavir

Inhibits 3CLpro

5

Ritonavir

Inhibits 3CLpro

6

Darunavir and cobicistat

Inhibits 3CLpro

(Cheng et al., 2015)
(Arabi et al., 2018; Kim et al., 2015;
Sheahan et al., 2020)
(Arabi et al., 2018; Kim et al., 2015;
Sheahan et al., 2020)
( Lu, 2020)15

7

ASC09F (HIV protease inhibitor) Inhibits 3CLpro

(Xiaowei Xu, Jian Liu, 2020)16

8

Nafamostat

(Ito et al., 2016; Wang et al., 2020b)

9

Griffithsin

10

Arbidol (Umifenovir)

11

Oseltamivir

Inhibits spike-mediated membrane fusion
Griffithsin binds to the SARS-CoV spike
glycoprotein, thus inhibiting viral entry
Not known
Oseltamivir is an influenza neuraminidase
inhibitor.

Host-based treatment strategies
12

Recombinant Interferons (a & b) Exogenous interferons

13

Nitazoxanide

14

Cyclosporine A

15

Alisporivir

16

Selumetinib

17

Trametinib

18

Rapamycin

19

K11777, Camostat

20

Mycophenolic acid

21

Silvestrol

Induces the host innate immune response
to produce interferons (a & b) by the host’s
fibroblasts and protein kinase R (PKR)
activation
Cyclophilin inhibitor
Cyclophilin inhibitor
Inhibits the ERK/MAPK and PI3K/AKT/
mTOR signalling pathways
Inhibits the ERK/MAPK and PI3K/AKT/
mTOR signalling pathways
Inhibits the ERK/MAPK and PI3K/AKT/
mTOR pathways significantly inhibited
MERS-CoV replication
Blocks endosomal protease-mediated
cleavage and the endosomal entry pathway
Inhibits IMPDH and guanine
monophosphate synthesis

(Barton et al., 2014; O’Keefe et al., 2010)
(Burke, 17 FEB)17
(Huang et al., 2020)
(Falzarano et al., 2013; Kim et al., 2015;
O’Keefe et al., 2010)
(Rossignol, 2014)
(Pfefferle et al., 2011)
(de Wilde et al., 2017b)
(Kindrachuk et al., 2015)
(Kindrachuk et al., 2015)
(Kindrachuk et al., 2015)
(Zhou et al., 2015)
(Hart et al., 2014)

Inhibits the DEAD-box RNA helicase eIF4A
(Müller et al., 2018)
to affect virus translation

15
Lu H (2020). Efficacy and Safety of Darunavir and Cobicistat for Treatment of COVID-19 (DC-COVID-19). [online] Website:
https://clinicaltrials.gov/ct2/show/record/NCT04252274 [accessed 7 May 2020]
16
Xu X, Liu J (2020). Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel
Coronavirus Infection. [online] Website: https://clinicaltrials.gov/ct2/show/NCT04261907 [accessed 7 May 2020]
17
Burke CW (2020). Mobilizing drug development efforts against the novel coronavirus. [online]. Website: https://www.biospace.
com/article/mobilizing-drug-development-efforts-against-the-novel-coronavirus/ [accessed 7 May 2020].
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MERS. The whole-genome sequence of SARS-CoV-2
has been identified which will provide more options for
the development of diagnosis and treatment. It is very
unfortunate for us that there is no medicine or vaccine
available yet although several research institutes and drug
manufacturer companies have announced to develop
vaccines. The drug repurposing has emerged as a basic
clinical tool to find new molecular entities having an
impact on treating associated disease. The existing drugs
help to reduce the cost of development and time and they
have a higher rate of success. Research on a number of
existing drugs having antiviral activity is underway across
the world.
After starting in 2019, this pandemic continued to spread
around the world. And this put the world in a big financial
crisis. The Economist reported a 6% slowdown of the
world’s economy in this year, 0.7% of growth and the
average 1.2% contraction. It is still difficult to estimate how
much more this will affect the economy; this will definitely
depend on how long it will take to discover a vaccine or
drug.
11. Conclusion
The previous epidemic in the 19th–20th century and
now this COVID-19 made people and governments all
over the world realize the importance of public health
and now how this could be a key factor in improving the
global life expectancy in the near future. The economic
disruption and discontinuation of the manufacturing
supply chain of goods across the world are indeed a matter
of great concern too because the varying per day new
cases of COVID-19 across the globe painfully exposes

the current and persisting health inequalities in our
society and emphasizes the crucial necessity of collective
action of various countries, institutions, academics, and
pharmaceutical companies against this outbreak across
the world. However, public health bodies should keep an
eye on the situation closely, as the more we know about
this deadly virus and its associated outbreak, the better we
can respond.
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WHO

World Health Organization

CDC

Center For Disease Control and Prevention

COVID-19

Coronavirus Disease-2019

HCoVs

Human Coronaviruses

HBV

Hepatitis B Virus

MERS

Middle East Respiratory Syndrome

HCoV

Human Coronavirus

MERS-CoV Middle East Respiratory Syndrome Coronavirus

HCV

Hepatitis C Virus

ARDS

Acute Respiratory Distress Syndrome

IAV

Influenza A Virus

PLpro

Papain-Like Protease

SPHCC

Shanghai Public Health Clinic Center

ICTV

International Committee on Taxonomy of Viruses

NCIP

Novel Corona Virus-Infected Pneumonia

MOF

Multiple Organ Failure

TCM

Traditional Chinese Medicine

LAIV

Live-Attenuated Investigational Vaccine

WTTC

World Travel and Tourism Council

ICAO

International Civil Aviation Organization

RdRp

RNA-Dependent RNA Polymerase

RSV

Respiratory Syncytial Virus

SARS-CoV Severe Acute Respiratory Syndrome Coronavirus

IEA

International Energy Agency
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